vida: extract claims from 2025-truveta-ispor-glp1-discontinuation-reasons

- Source: inbox/queue/2025-truveta-ispor-glp1-discontinuation-reasons.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -140,3 +140,10 @@ Topics:
 **Source:** JMIR 2025 (e69466) + Omada Health real-world data
 
 Omada Health's Enhanced GLP-1 Care Track achieved 67% persistence at 12 months (vs. 47-49% baseline) through integrated digital behavioral support, suggesting low persistence rates may be addressable through intervention design rather than being an immutable patient characteristic. The 20 percentage point improvement demonstrates that the structural intervention opportunity is substantial.
+
+
+## Supporting Evidence
+
+**Source:** Truveta Research ISPOR 2025
+
+Truveta confirms indication-specific persistence gap: T2D indication shows 64.8% annual discontinuation versus 46.5% for obesity-only, reinforcing that diabetes patients maintain therapy at higher rates than obesity-only patients.

domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md

@@ -53,3 +53,10 @@ WHO guideline specifies GLP-1 therapies for 'long-term obesity treatment (define
 **Source:** eClinicalMedicine/Lancet 2025 systematic review and meta-analysis (PMC12535773)
 
 Meta-analysis of discontinuation studies shows weight regain is proportional to original weight loss: liraglutide patients regained 2.20 kg, while semaglutide/tirzepatide patients regained 9.69 kg. Most patients regain two-thirds of prior weight loss within 6 months of stopping. Cardiometabolic benefits (blood pressure, lipids, CVD risk) reverse along with weight regain, confirming that GLP-1 suppression of appetite is pharmacological rather than behavioral modification. When drug is withdrawn, underlying neurobiological hunger signals return to baseline.
+
+
+## Extending Evidence
+
+**Source:** Truveta Research ISPOR 2025
+
+Truveta's discontinuation predictor analysis reveals that patients with cardiovascular disease or other chronic conditions are 10% more likely to discontinue despite having the strongest clinical indication for continuous therapy, suggesting that comorbidity burden creates adherence barriers even when clinical benefit is highest.

domains/health/glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Psychiatric comorbidity predicts GLP-1 discontinuation independent of other factors, compounding existing access barriers for the population with highest metabolic disease burden
+confidence: experimental
+source: Truveta Research ISPOR 2025 presentation, real-world EHR data
+created: 2026-04-27
+title: GLP-1 discontinuation is 12 percent higher among patients with psychiatric medication history creating an access-adherence trap where highest-need populations have lowest persistence
+agent: vida
+sourced_from: health/2025-truveta-ispor-glp1-discontinuation-reasons.md
+scope: correlational
+sourcer: Truveta Research
+supports: ["behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
+related: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation"]
+---
+
+# GLP-1 discontinuation is 12 percent higher among patients with psychiatric medication history creating an access-adherence trap where highest-need populations have lowest persistence
+
+Truveta's analysis of real-world GLP-1 discontinuation patterns found that patients with a history of psychiatric medication use are 12 percent more likely to discontinue GLP-1 therapy compared to those without psychiatric history. This creates a compounding access-adherence trap: patients with co-occurring mental health and metabolic conditions face the highest obesity burden and metabolic disease risk, yet are systematically less likely to both access GLP-1s (due to income and coverage barriers documented in KFF data) AND maintain therapy when they do gain access. The psychiatric comorbidity effect operates independently of income, age, and other comorbidity factors, suggesting a distinct mechanism—potentially related to medication burden, side effect tolerance, or behavioral health system fragmentation. This finding reveals that the population most likely to benefit from GLP-1 therapy (those with multiple chronic conditions including mental health disorders) faces a double barrier: structural access limitations followed by adherence failure even when access is achieved.

domains/health/glp1-long-term-persistence-ceiling-14-percent-year-two.md

@@ -44,3 +44,10 @@ PHTI December 2025 report documents employer payer response to low GLP-1 persist
 **Source:** eClinicalMedicine/Lancet 2025 discontinuation meta-analysis
 
 The biological mechanism underlying low persistence creates a clinical revolving door: when patients discontinue (which 85% do by year two), they regain two-thirds of lost weight within 6 months. For semaglutide/tirzepatide users, mean regain is 9.69 kg. This means the 14% persistence ceiling isn't just an adherence problem—it's a structural barrier to population health impact, as discontinued patients return to near-baseline metabolic state within months.
+
+
+## Extending Evidence
+
+**Source:** Truveta Research ISPOR 2025
+
+Truveta data shows the first 4 weeks (titration phase) are the highest-risk period for dropout, with persistence improving after initial titration but remaining below 50% for non-T2D patients. This temporal pattern suggests that interventions targeting the titration phase could disproportionately improve long-term persistence.

domains/health/glp1-persistence-improves-with-specialist-care-supporting-obesity-medicine-infrastructure.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Provider specialty predicts GLP-1 persistence independent of patient factors, suggesting care delivery model affects adherence outcomes
+confidence: experimental
+source: Truveta Research ISPOR 2025 presentation
+created: 2026-04-27
+title: Endocrinologists and obesity specialists achieve higher GLP-1 12-week completion rates than primary care providers supporting specialized obesity medicine infrastructure investment
+agent: vida
+sourced_from: health/2025-truveta-ispor-glp1-discontinuation-reasons.md
+scope: correlational
+sourcer: Truveta Research
+supports: ["glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support"]
+related: ["digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-long-term-persistence-ceiling-14-percent-year-two", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x"]
+---
+
+# Endocrinologists and obesity specialists achieve higher GLP-1 12-week completion rates than primary care providers supporting specialized obesity medicine infrastructure investment
+
+Truveta's real-world analysis found that patients receiving GLP-1 therapy from endocrinologists and obesity specialists demonstrate higher 12-week completion rates compared to those treated by primary care providers. This specialist advantage persists after controlling for patient-level factors including income, comorbidities, and indication. The mechanism likely involves multiple pathways: specialists may provide more intensive titration management, better side effect mitigation, more comprehensive nutritional counseling, or stronger patient education about the chronic nature of obesity treatment. This finding supports policy arguments for investing in specialized obesity medicine infrastructure rather than relying solely on primary care distribution. However, it also creates a tension: specialist care improves persistence but reduces access (fewer specialists, longer wait times, geographic concentration), while primary care maximizes access but produces lower persistence. The optimal system design must balance these competing objectives—potentially through collaborative care models where specialists support primary care prescribing rather than replacing it.

domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md

@@ -1,31 +1,15 @@
 ---
 type: claim
 domain: health
-description: "Income level correlates with GLP-1 discontinuation rates in commercially insured populations, indicating that cost-sharing and affordability barriers drive adherence as much as clinical factors like side effects or insufficient weight loss"
+description: Income level correlates with GLP-1 discontinuation rates in commercially insured populations, indicating that cost-sharing and affordability barriers drive adherence as much as clinical factors like side effects or insufficient weight loss
 confidence: experimental
 source: "Journal of Managed Care & Specialty Pharmacy, Real-world Persistence and Adherence to GLP-1 RAs Among Obese Commercially Insured Adults Without Diabetes, 2024-08-01"
 created: 2026-03-11
-related_claims:
-  - divergence-glp1-economics-chronic-cost-vs-low-persistence
-related:
-- federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings
-- glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints
-- pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling
-- GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months
-- Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?
-reweave_edges:
-- federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings|related|2026-03-31
-- glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints|related|2026-03-31
-- pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling|related|2026-03-31
-- GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months|related|2026-04-04
-- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04
-- GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs|supports|2026-04-14
-- Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?|related|2026-04-17
-supports:
-- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations
-- GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs
-sourced_from:
-- inbox/archive/health/2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations.md
+related_claims: ["divergence-glp1-economics-chronic-cost-vs-low-persistence"]
+related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints", "pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling", "GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months", "Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi"]
+reweave_edges: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings|related|2026-03-31", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints|related|2026-03-31", "pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling|related|2026-03-31", "GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months|related|2026-04-04", "GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04", "GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs|supports|2026-04-14", "Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?|related|2026-04-17"]
+supports: ["GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations", "GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs"]
+sourced_from: ["inbox/archive/health/2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations.md"]
 ---
 
 # Lower-income patients show higher GLP-1 discontinuation rates suggesting affordability not just clinical factors drive persistence
@@ -90,4 +74,10 @@ Relevant Notes:
 - [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]
 
 Topics:
-- domains/health/_map
+- domains/health/_map
+
+## Supporting Evidence
+
+**Source:** Truveta Research ISPOR 2025
+
+Truveta ISPOR 2025 data confirms income >$80,000 predicts lower discontinuation rates even among commercially insured patients, demonstrating that financial access affects adherence independent of insurance coverage status. The income effect persists after controlling for comorbidities, age, and provider type.

inbox/archive/health/2025-truveta-ispor-glp1-discontinuation-reasons.md

@@ -7,9 +7,12 @@ date: 2025-01-01
 domain: health
 secondary_domains: []
 format: conference-presentation
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-27
 priority: medium
 tags: [glp-1, discontinuation, real-world, ISPOR, drivers, adherence, income, comorbidities, side-effects]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content